Mutation analysis of three genes encoding novel LKB1-interacting proteins, BRG1, STRADα, and MO25α, in Peutz–Jeghers syndrome by Alhopuro, P et al.
Short Communication
Mutation analysis of three genes encoding novel LKB1-interacting
proteins, BRG1, STRADa, and MO25a, in Peutz–Jeghers
syndrome
P Alhopuro
1, P Katajisto
2, R Lehtonen
1, SK Ylisaukko-oja
1,LN a ¨a ¨tsaari
1, A Karhu
1, AM Westerman
3,
JHP Wilson
3, FWM de Rooij
3, T Vogel
4, G Moeslein
5, IP Tomlinson
6, LA Aaltonen
1,T PM a ¨kela ¨
2 and
V Launonen*,1
1Department of Medical Genetics, Biomedicum Helsinki (Haartmaninkatu 8), University of Helsinki, Helsinki FIN-00014, Finland;
2Molecular Cancer
Biology Program, Institute of Biomedicine and Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, Finland;
3Laboratory of Vascular and
Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands;
4Unfallchirurgie, Universita ¨tsklinikum,
Heinrich Heine Universita ¨t, Du ¨sseldorf, Germany;
5Allgemein- und Viszeralchirurgie, Universita ¨tsklinikum, Heinrich Heine Universita ¨t, Du ¨sseldorf, Germany;
6Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 44, Lincoln’s Inn Fields, London WC2A 3PX, UK
Mutations in LKB1 lead to Peutz–Jeghers syndrome (PJS). However, only a subset of PJS patients harbours LKB1 mutations. We
performed a mutation analysis of three genes encoding novel LKB1-interacting proteins, BRG1, STRADa, and MO25a,i n2 8LKB1-
negative PJS patients. No disease-causing mutations were detected in the studied genes in PJS patients from different European
populations.
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Peutz–Jeghers syndrome (PJS) is an autosomal dominantly
inherited disorder characterised by mucocutaneous pigmentation,
hamartomatous polyps of the gastrointestinal tract, and a
predisposition to cancer at a young age (Giardiello et al, 1987,
2000; Hemminki, 1999). The majority of cancers in PJS patients
occur in the stomach and upper small bowel, whereas the most
frequently diagnosed extraintestinal cancers are those of the
pancreas, breast, and testis (Giardiello et al, 1987).
Inactivating mutations in the serine–threonine kinase LKB1
(STK11) have been causally linked to PJS (Hemminki et al, 1997,
1998; Jenne et al, 1998). However, 30–82% of PJS patients have no
detectable LKB1 mutations, suggesting locus heterogeneity (Lim
et al, 2003, and references therein). Moreover, some families have
been reported to be clearly unlinked to LKB1 locus (Mehenni et al,
1997; Olschwang et al, 1998). Linkage analysis has previously
yielded a second locus on chromosome 19q13.4, and recently, a
translocation breakpoint was mapped to the same locus, but
several genes within this region have subsequently been excluded
from having a role in PJS (Mehenni et al, 1997; Buchet-Poyau et al,
2002; Hearle et al, 2004). Thus, current candidates for the second
PJS loci are genes known or suggested to interact with LKB1 either
by direct association or functionally.
LKB1 has been suggested to mediate its cellular functions
through interactions with a number of proteins including LIP1,
BRG1, MO25a and STRADa (Marignani et al, 2001; Buchet-Poyau
et al, 2002; Baas et al, 2003; Boudeau et al, 2003). Of these, BRG1 is
appealing, as Brg1 heterozygous mice form epithelial subcutaneous
tumours (Bultman et al, 2000). LKB1 has been proposed to
associate with and stimulate BRG1, and LKB1 might have a role in
BRG1-dependent growth arrest (Marignani et al, 2001). Both
STRADa and MO25a have been identified by two independent
methods: by probing AMPKK fractions using antibodies against
LKB1, STRADa, and MO25a, and by purification of LKB1 binding
proteins (Baas et al, 2003; Boudeau et al, 2003; Brajenovic et al,
2004). STRADa is the first identified LKB1 substrate in vivo.
Furthermore, both STRADa and MO25a have been shown to
translocate LKB1 from the nucleus to cytoplasm, and interestingly,
previous studies have shown that cytoplasmic localisation is
significant for LKB1 growth suppressive function (Tiainen et al,
1999, 2002).
Of the LKB1-interacting proteins, only LIP1 (Buchet-Poyau et al,
2002) has been analysed as a candidate for a second PJS locus.
Here, we have extended this approach by analysing three
interesting genes encoding LKB1-interacting proteins: BRG1,
STRADa, and MO25a.
MATERIALS AND METHODS
A total of 27 LKB1 mutation-negative PJS patients from four
different European countries (seven from Finland, eight from UK,
two from the Netherlands, and 10 from Germany) were included in
the study. A diagnosis of PJS was made when the patient presented
with two or more PJS polyps, one polyp and typical pigmented
lesions, or one polyp and a family history of PJS (Tomlinson and
Houlston, 1997). Additionally, one Finnish patient who had been
diagnosed with a single PJS polyp at the age of 29 years, with
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sunknown family history, was included in the mutation screening.
Sporadic disease was diagnosed in 15 (54%) patients and familial
disease in 10 patients (36%). No family history was available from
three patients. DNA extraction was performed using standard
methods. Healthy controls were obtained from the Finnish Red
Cross Blood Transfusion Service.
All 34 coding exons and the flanking intronic sequences of BRG1
(NM_003072.1) were amplified in 38 fragments. Denaturing high-
performance liquid chromatography (DHPLC) method was used in
preliminary mutation screening with automated HPLC instrumen-
tation (Agilent Technologies, Palo Alto, CA, USA), and Helix DNA
50 3.0mm 1/400 analytical column (Varian Inc. Palo Alto, CA,
USA). Optimal melting temperatures for each amplicon were
obtained using an algorithm at the Stanford DHPLC Melt program
web page (http://insertion.stanford.edu/melt1.html). The analytical
acetonitrile gradient was composed by mixing Helix BufferPak A
for DHPLC and 55–75% B (Varian) at flow rate of 0.4mlmin
 1.
All samples displaying aberrant or ambiguous pattern in DHPLC
were reanalysed by sequencing with ABI 3730 sequencer (Applied
Biosystems, Foster City, CA, USA). Polymerase chain reaction
(PCR) primers are available from the authors upon request.
The mutation screening of the 12 coding exons of STRADa
(BK001542.1), the eight coding exons of MO25a (NM_016289.2),
and the flanking intronic regions was performed by genomic
sequencing using Applied Biosystems 3730 sequencing analyzer.
Polymerase chain reaction conditions and primer sequences are
available from the authors upon request.
The potential effect of silent polymorphisms, intronic, and UTR
changes to splicing were predicted by computational methods
using NetGene2 splice site prediction web server (http://geno-
me.cbs.dtu.dk/services/NetGene2/). Silent polymorphisms in exons
5 and 27 of BRG1 were predicted to alter splicing in silico. The
polymorphism in exon 5 was predicted to increase the probability
of cryptic acceptor splice sites flanking the mutation site, whereas
in exon 27, a new cryptic donor splice site was predicted. To study
the effect at the RNA level, RNA from cultured lymphoblasts was
extracted, and reverse transcriptase–PCR (RT–PCR) reactions
and cDNA amplifications were performed using standard proto-
cols. Potential splicing variants were visualised by 2% agarose gel
electrophoresis. Furthermore, to detect possible effects of altered
splicing to expression, real-time PCR was performed using ABI
Prism 5700 sequence detection system (Applied Biosystems) and
SYBR Green PCR master mix (Applied Biosystems). cDNA samples
from two unaffected individuals were used as controls. Primers
used were as follows: 50-AAGCCCTGGCCTGAAGGA-30 and 50-
TGCGGGGGAATCAGCTTCT-30 for the exon 5 change and
50-GGCGTCAACCCCGACTT-30 and 50-TGCGCATGAACAGAT
CAAACTC-30 for the exon 27 change. The reverse primers were
designed so that they located in the potentially spliced cDNA
segment. GAPDH and TBP were used as control genes to normalise
the reactions.
RESULTS AND DISCUSSION
To determine whether BRG1, STRADa,o rMO25a are mutated in
LKB1 mutation-negative PJS patients, we performed a mutation
screening in a set of 28 patient samples. Mutation analysis of BRG1
was performed by DHPLC. The sensitivity of the method has been
shown to vary between 93 and 100%, consistently exceeding 96%
(Xiao and Oefner, 2001). In BRG1, two novel silent changes were
observed (Table 1). A Pro327Pro (c.980A4C) change in exon 5
and a Pro1297Pro (c.3890C4G) change in exon 27 were both
found in 4% (one of 28) of the subjects (allele frequency 2%). The
Pro1297Pro variant was also detected in healthy controls (two of
188, allele frequency 0.5%), whereas DHPLC analysis of 267
healthy controls revealed no Pro327Pro changes. Splicing effects of
these variants were subsequently tested in silico, and the
Pro327Pro change was predicted to alter acceptor splice site of
exon 5 and the Pro1297Pro change to create a potentially new
donor splicing site. To further discern the effects of these variants
to splicing, RT–PCR analysis was performed. However, no
alternate transcripts were detected at the RNA level (Figure 1).
Furthermore, quantitative real-time PCR was performed to detect
possible changes in expression caused by alternative splicing.
Means of normalised expressions of BRG1 were 1.5 (s.d. 0.14) and
1.4 (s.d. 0.31) in patient with Pro327Pro and normal controls,
respectively. Means of normalised expressions of BRG1 were 1.6
(s.d. 0.28) and 1.4 (s.d. 0.26) in patients with Pro1297Pro and
normal controls, respectively. Thus, no decrease in BRG1
expression levels was observed in patients with Pro327Pro and
Pro1297Pro mutations when compared to controls.
Five previously reported silent polymorphisms were detected:
Ala503Ala, His508His, Asp1351Asp, Asp1528Asp, and Asp1628Asp
(Valdman et al, 2003; Medina et al, 2004, http://www.ensembl.org).
Also, a previously described missense polymorphism, Tyr372His,
was found in two PJS patients (Medina et al, 2004). Additionally,
six intronic variants were observed (Table 1). Splicing effect of
all intronic variants was subsequently tested in silico. One of
the variants, IVS17-4C4A, gave little evidence of alternative
splicing. The IVS17-4C4A change was found in one PJS patient,
but not in 186 healthy controls (Table 1). The effects of this variant
could not be studied at the RNA level, because no sample was
available.
Table 1 Summary of BRG1 polymorphisms identified in the study
Location Variant Allele frequency (%) in PJS (no. of patients) Allele frequency (%) in controls Reference
Exon 5 Pro327Pro, c.980A4C 2 (1/28) 0 (0/267) This study
Exon 5 Tyr372His, c.1114T4C 4 (2/28) — Medina et al (2004)
Exon 8 Ala503Ala, c.1509A4C 2 (1/27) — Medina et al (2004)
Exon 8 His508His, c.1524T4C 19 (8/27) — Ensembl
a
Exon 27 Pro1297Pro, c.3890C4G 2 (1/28) 0.5 (2/188) This study
Exon 28 Asp1351Asp, c.4333C4T 7 (3/28) — Valdman et al (2003)
Exon 31 Asp1528Asp, c.4584C4T 4 (2/28) — Ensembl
a
Exon 33 Asp1628Asp, c.4886T4C 9 (4/28) — Ensembl
a
Intron 9 IVS9+29G4A 2 (1/25) — This study
Intron 9 IVS9 37T4C 32 (13/24) — This study
Intron 13 IVS13+12C4T 2 (1/28) — This study
Intron 17 IVS17+55G4A 5 (3/28) — This study
Intron 17 IVS17 4C4A 2 (1/28) 0 (0/186) This study
Intron 32 IVS32 44C4T 2 (1/28) — This study
—, not tested in this study.
ahttp://www.ensembl.org.
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at position 96 (allele frequency 63%), was observed in the
noncoding sequence of exon 2. Moreover, three intronic poly-
morphisms were detected. Sequencing of MO25a revealed one
intronic and two 30UTR polymorphisms. The detected variants in
STRADa and MO25a (Table 2) were not predicted to affect splicing
in silico.
Several previous studies support the hypothesis of locus
heterogeneity of PJS. However, linkage data and candidate gene
approach have not yielded a second PJS gene (Buchet-Poyau et al,
2002). Little has been known about LKB1-interacting proteins until
recently. Cellular functions suggested for LKB1 to date include an
ability to induce cell cycle arrest through p21, involvement in p53-
dependent apoptosis pathway and VEGF signalling, involvement in
BRG1-dependent chromatin remodelling, induction of colon
epithelial cell polarity, and contribution to cell stress censoring
through activation of the AMPK kinases (Tiainen et al, 1999;
Karuman et al, 2001; Marignani et al, 2001; Ylikorkala et al, 2001;
Baas et al, 2003; Hawley et al, 2003). Furthermore, the recent
demonstration that LKB1 acts as an in vivo activating kinase for at
least 13 other kinases suggests that LKB1 will be involved in several
as yet uncharacterised functions (Lizcano et al, 2004).
Proteins interacting with LKB1 and enhancing its tumour
suppressor function are attractive candidates for the second PJS
locus. Here, we analysed three genes encoding LKB1-interacting
proteins: BRG1, STRADa, and MO25a. While our approach is
unable to detect some mutation types, such as large deletions, the
results suggest that germline mutations in these three genes have
no major contribution to PJS. These genes were selected as the best
candidates at the initiation of the study. Nevertheless, the recent
identification of a number of in vivo substrates of LKB1 as well as
the identification of MO25b and STRADb provide several novel
interesting candidates to be analysed in subsequent studies
(Boudeau et al, 2003; Lizcano et al, 2004).
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